-

AbCellera to Present Virtually at Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences:

  • BMO Biopharma Spotlight Series: Technology-Enabled Drug Discovery Panel on Friday, April 16, 2021 at 7:00 a.m. Pacific Time
  • 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20 at 10:30 a.m. Pacific Time

Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera’s Investor Relations website. A replay of each webcast will be available through the same links following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

Source: AbCellera Biologics Inc.

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Kevin Heyries, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

AbCellera Biologics Inc.

NASDAQ:ABCL

Release Summary
AbCellera to Present Virtually at Upcoming Investor Conferences
Release Versions
$Cashtags

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Kevin Heyries, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
More News From AbCellera Biologics Inc.

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026...

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause...

AbCellera and Bruker Reach Global Settlement of Patent Litigation

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera and Bruker Reach Global Settlement of Patent Litigation...
Back to Newsroom